The safety profile of MSD’s Keytruda in this trial was in line with prior studies. Credit: Tada Images / Shutterstock.

Merck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial evaluating Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The randomised, double-blind KEYNOTE-811 trial assessed Keytruda plus trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial’s dual primary endpoints were progression-free survival (PFS) and overall survival (OS), while secondary endpoints comprised objective response rate (ORR), duration of response, and safety.

Enrolling 698 subjects, the trial compared Keytruda 200mg given every three weeks in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, versus placebo in combination with trastuzumab and chemotherapy.

According to the latest data, the study met its dual primary endpoint of overall survival (OS), showing a significant improvement in patients treated with the Keytruda regimen.

See Also:

The final analysis also confirmed that the Keytruda combination regimen led to a statistically significant and clinically meaningful improvement in OS in the intention-to-treat (ITT) study population, particularly those with PD-L1-expressing tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Keytruda’s safety profile in this trial was in line with prior studies, and no new safety signals were identified.

An earlier interim analysis had demonstrated that the Keytruda regimen met the other primary endpoint of PFS.

Following the earlier results, the US Food and Drug Administration (FDA) gave accelerated approval to Keytruda in combination with trastuzumab and chemotherapy as first-line treatment for adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumours express PD-L1.

Merck Research Laboratories’ global clinical development oncology head and senior vice-president Dr Marjorie Green said: “Patients diagnosed with advanced gastric cancer often face a poor prognosis, underscoring the need for treatment options that have the potential to extend patients’ lives.

“These overall survival results from KEYNOTE-811 are encouraging and build on the positive progression-free survival, overall response rate and duration of response data from this study.”

Last month, MSD announced positive data from the Phase III STRIDE-10 trial of its investigational pneumococcal conjugate vaccine, V116.